OK Thank you.

Thanks for it's great to be here.

I have my first trip to Georgia Tech.

Although as you heard not to Atlanta and
only thing I wanted to ask you

all of my slides have a dark background so
do we need to adjust the lights for

you guys I mean I know what's on them but
it's probably going to be better for you.

OK so I'm happy it's not
a very long presentation and

if you need want to ask questions
throughout that's completely fine.

I want to tell you about some
work that we did studying

in the iron import system
in nice Syria and we got

we started working on this was when I was
an investigator before I went to the and

I H I had a sort of an investigator
position at Birkbeck College in London and

which is part of the University
of London system and in the U.K.

at least men and bacterial
meningitis is a pretty big problem.

So there are now vaccines available and
some of you or your kids may have been

vaccinated but the only thing and
as I'll tell you the only one that

isn't protected against right now is here
a group B. And so we set out to work

on proteins that are antigenic that were
vaccine targets against Syria Group B.

meningitis and so that's where
that's how we got started on this.

So nice Syria manage it.

It is a gram negative bacteria.

And as I just mentioned there
are multiple sirrah typesetter and

associated with disease.

Those are A B C Y N W one thirty five and

the vaccines prayer presently available
treat against everything but B.

But there are problems with
the ones that are out right now and

meningitis gives produces septicemia

which is through the blood and
meningitis when it acts on the brain.

You can treat with antibiotics and

if you do so in time they're pretty
effective and there are vaccines.

But the ones that are available
don't protect very young people or

people older than fifty five and.

Even the current vaccine has some issues
so there were reasons to do this work.

I guess.

And yes I just told you that
there are no vaccines against it.

It is interesting to know that all of
this is pathogenic in some instances

ten to forty percent of us carry NIH Syria
minute it is in our nasal passages and

in fact my Syria are obligate human
pathogens they don't exist in the soil or

anywhere else just in us.

That's the only place
that they can grow and so

most of the time they don't cause
any problems at all and then for

some reason this once in a while there
is an outbreak and they multiply and

do all sorts of damage mostly through
the septicemia that I noted and

that you know is they they multiply to the
extent that your body produces this huge

immune response and that's what
that's what gives us the side effects

that we have and
those kind of side effects that

occur are ten to fifteen percent die
even after antibiotic treatment and

other survivors a good number of
people suffer long term effects such

as seizures or stroke deafness
neurological deficit and or limb loss.

And so currently what I what I didn't say
a moment ago is so there is now a vaccine

in phase three clinical trials
it's going to be very good and so

the work that we did after fourteen years
it might not be surprising that it's

not quite as relevant
as it was back then but

nice Syria managed to this is closely
related to NIH Syria gonorrhea

which causes a sexually transmitted
disease going Urrea there are seven

hundred thousand cases reported every year
in the U.S. There is no multi-discipline

multi-drug resistant form of NIH Syria
gonorrhea not treatable by anything.

It's just

so sick.

It's.

It's.

It's.

IT'S IT'S

IT'S IT'S IT'S IT'S

IT'S

IT'S IT'S IT'S IT'S

IT'S IT'S

IT'S

IT'S IT'S

IT'S IT'S

IT'S IT'S IT'S

IT'S IT'S.

It's.

It's.

It's.